Lilydale Inc., Edmonton is warning the public not to consume the Lilydale Cooked Seasoned Sliced Turkey Breast described below because it may be contaminated with Salmonella.
Shire plc today announced the availability of LIALDATM (mesalamine) with MMXTM Technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), a type of inflammatory bowel disease. LIALDA is the first and only FDA-approved once daily oral formulation of mesalamine. The US Food and Drug Administration approved LIALDA on Jan. 16, 2007.
The U.S. Food and Drug Administration (FDA) cleared for marketing a test that uses molecular biology to quickly detect the presence of viral meningitis.
A University of Iowa study may provide an explanation for why some people get migraine headaches while others do not. The researchers found that too much of a small protein called RAMP1 appears to “turn up the volume” of a nerve cell receptor’s response to a neuropeptide thought to cause migraines.
The Hong Kong Department of Health (DH) urged members of the public not to buy or use four brands of health products and two brands of proprietary Chinese medicines after finding them to have contained potentially hazardous ingredients that may cause side effects.
The Food and Drug Administration (FDA) told 20 companies to cease marketing unapproved drug products containing ergotamine tartrate.
The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are reminding consumers of the dangers of drinking milk that has not been pasteurized, known as raw milk.
A new candidate vaccine against hepatitis E, developed collaboratively by GlaxoSmithKline (GSK) and the Walter Reed Army Institute of Research (WRAIR), was found to be 95.5% effective in a Phase Two trial, according to a study to be published in the New England Journal of Medicine.
A new report from the World Health Organization (WHO) shows that neurological disorders, ranging from epilepsy to Alzheimer disease, from stroke to headache, affect up to one billion people worldwide.
On 22 February 2007 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending to grant a marketing authorisation for the medicinal product Sebivo, 600 mg, film-coated tablet intended for treatment of chronic hepatitis B virus (HBV) infection in adult patients.